Enzymolysis peptides from Mauremys mutica plastron improve the disorder of neurotransmitter system and facilitate sleep-promoting in the PCPA-induced insomnia mice

2021 ◽  
Vol 274 ◽  
pp. 114047
Author(s):  
Yan-bo Lv ◽  
Qing Zhou ◽  
Jia-xing Yan ◽  
Lin-song Luo ◽  
Jiu-liang Zhang
2009 ◽  
Vol 32 (5) ◽  
pp. 649-656 ◽  
Author(s):  
Wei-Hua ZHAO ◽  
Xin-Ping ZHU ◽  
Cheng-Qing WEI ◽  
He-Jun DU ◽  
Yong-Le CHEN

2021 ◽  
Vol 5 ◽  
pp. 247054702110204
Author(s):  
Julia Hecking ◽  
Pasha A. Davoudian ◽  
Samuel T. Wilkinson

Mood disorders represent a pressing public health issue and significant source of disability throughout the world. The classical monoamine hypothesis, while useful in developing improved understanding and clinical treatments, has not fully captured the complex nature underlying mood disorders. Despite these shortcomings, the monoamine hypothesis continues to dominate the conceptual framework when approaching mood disorders. However, recent advances in basic and clinical research have led to a greater appreciation for the role that amino acid neurotransmitters play in the pathophysiology of mood disorders and as potential targets for novel therapies. In this article we review progress of compounds that focus on these systems. We cover both glutamate-targeting drugs such as: esketamine, AVP-786, REL-1017, AXS-05, rapastinel (GLYX-13), AV-101, NRX-101; as well as GABA-targeting drugs such as: brexanolone (SAGE-547), ganaxolone, zuranolone (SAGE-217), and PRAX-114. We focus the review on phase-II and phase-III clinical trials and evaluate the extant data and progress of these compounds.


2015 ◽  
Vol 27 (4) ◽  
pp. 2466-2467 ◽  
Author(s):  
Jian Zhao ◽  
Wei Li ◽  
Dandan Zhang ◽  
Ping Wen ◽  
Xinping Zhu

Neuron ◽  
2011 ◽  
Vol 72 (2) ◽  
pp. 316-329 ◽  
Author(s):  
Elizabeth S. Brooks ◽  
Christina L. Greer ◽  
Rafael Romero-Calderón ◽  
Christine N. Serway ◽  
Anna Grygoruk ◽  
...  

2012 ◽  
Vol 2 (6) ◽  
pp. 241-254 ◽  
Author(s):  
Zerrin Atakan

Cannabis is a complex plant, with major compounds such as delta-9-tetrahydrocannabinol and cannabidiol, which have opposing effects. The discovery of its compounds has led to the further discovery of an important neurotransmitter system called the endocannabinoid system. This system is widely distributed in the brain and in the body, and is considered to be responsible for numerous significant functions. There has been a recent and consistent worldwide increase in cannabis potency, with increasing associated health concerns. A number of epidemiological research projects have shown links between dose-related cannabis use and an increased risk of development of an enduring psychotic illness. However, it is also known that not everyone who uses cannabis is affected adversely in the same way. What makes someone more susceptible to its negative effects is not yet known, however there are some emerging vulnerability factors, ranging from certain genes to personality characteristics. In this article we first provide an overview of the biochemical basis of cannabis research by examining the different effects of the two main compounds of the plant and the endocannabinoid system, and then go on to review available information on the possible factors explaining variation of its effects upon different individuals.


1999 ◽  
Vol 81 (1) ◽  
pp. 408-411 ◽  
Author(s):  
Dax A. Hoffman ◽  
Daniel Johnston

Hoffman, Dax A. and Daniel Johnston. Neuromodulation of dendritic action potentials. J. Neurophysiol. 81: 408–411, 1999. The extent to which regenerative action potentials invade hippocampal CA1 pyramidal dendrites is dependent on both recent activity and distance from the soma. Previously, we have shown that the amplitude of back-propagating dendritic action potentials can be increased by activating either protein kinase A (PKA) or protein kinase C (PKC) and a subsequent depolarizing shift in the activation curve for dendritic K+ channels. Physiologically, an increase in intracellular PKA and PKC would be expected upon activation of β-adrenergic and muscarinic acetylcholine receptors, respectively. Accordingly, we report here that activation of either of these neurotransmitter systems results in an increase in dendritic action-potential amplitude. Activation of the dopaminergic neurotransmitter system, which is also expected to raise intracellular adenosine 3′,5′-cyclic monophosphate (cAMP) and PKA levels, increased action-potential amplitude in only a subpopulation of neurons tested.


Sign in / Sign up

Export Citation Format

Share Document